pd 142505-0028 has been researched along with pirenzepine in 1 studies
| Studies (pd 142505-0028) | Trials (pd 142505-0028) | Recent Studies (post-2010) (pd 142505-0028) | Studies (pirenzepine) | Trials (pirenzepine) | Recent Studies (post-2010) (pirenzepine) |
|---|---|---|---|---|---|
| 11 | 1 | 0 | 3,812 | 587 | 140 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Disterhoft, JF; Oh, MM; Preston, AR; Schwarz, RD; Weiss, C; Welty, D | 1 |
1 other study(ies) available for pd 142505-0028 and pirenzepine
| Article | Year |
|---|---|
The M1 muscarinic agonist CI-1017 facilitates trace eyeblink conditioning in aging rabbits and increases the excitability of CA1 pyramidal neurons.
Topics: Acoustic Stimulation; Action Potentials; Aging; Animals; Blinking; Bridged Bicyclo Compounds, Heterocyclic; Conditioning, Classical; Female; Hippocampus; Muscarinic Agonists; Oximes; Pirenzepine; Pyramidal Cells; Rabbits; Receptor, Muscarinic M1; Receptors, Muscarinic; Time Factors | 2000 |